CD8A and melanoma: While in our thyroid model we found HSV/BRAFi therapy to be significantly dependent on CD8 (but not CD4) cells,8 in this melanoma model we saw no significant difference in HSV/BRAFi/anti-CD25 treatment benefit with CD8 + or CD4+ depletion (data not shown).